April 20, 2026Journal of the American College of Cardiology
Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling
Why the study?
Clinicians need to understand the relationship between remodeling and HF progression to fully appreciate the potential benefits of HF therapies, amidst evolving goals in HF management and unclear roles for monitoring imaging.
Design
Consensus paper
Authors
Discussion
Loading...
Member takes
Implication
Prioritize ACEI and beta-blockers to reverse remodeling in HF; reinforces their benefit on a major driver of disease progression.
Key Points
- This consensus paper aims to clarify the role of cardiac remodeling in heart failure and its implications for therapy.
- Consensus discussion by experts at an international forum on cardiac remodeling
- Review of clinical data regarding heart failure treatment
- Consideration of therapeutic agents' effects on remodeling and outcomes
- Cardiac remodeling is a crucial determinant of heart failure progression and treatment efficacy.
- Therapeutic agents like ACE inhibitors and beta-adrenergic blockers show beneficial effects on remodeling and improve morbidity and mortality.
- The role of ejection fraction in guiding ongoing HF therapy remains debated.
PICO
P
Population
Heart failure
I
Intervention / Comparator
ACE inhibitors and beta-adrenergic blocking agents
This consensus paper defines cardiac remodeling and emphasizes the importance of understanding its relationship with heart failure progression to fully appreciate the benefits of therapies like ACE inhibitors and beta-blockers.
Cite This Study
Cohn et al. (2000) conducted a review in Heart failure. ACE inhibitors and beta-adrenergic blocking agents was evaluated. Therapeutic agents such as ACE inhibitors and beta-blockers provide beneficial effects on the cardiac remodeling process, which is a key determinant of heart failure progression.